Stock of the Day

Merus (MRUS)

$47.37

-$0.26 (-0.5%)

Market Cap: $3.26B

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Recent News

• Merus’ petosemtamab granted Breakthrough Therapy designation by FDA (markets.businessinsider.com)
• Merus’s Breakthrough in HNSCC: Buy Rating Backed by FDA Support and Promising Trial Data (tipranks.com)
• Merus NV (MRUS) Receives Second Breakthrough Therapy Designation for Petosemtamab in Head and ... (gurufocus.com)
• Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments (msn.com)
• 7MRUS : Merus Shares Are Up Today: What's Going On? (benzinga.com)
• Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma (globenewswire.com)
• Merus N.V.'s SWOT analysis: biotech firm's stock poised for growth amid clinical trials (msn.com)